Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...
Recursion said today it is eliminating approximately 20% of its workforce—about 160 jobs—in a restructuring the AI-based drug developer said reflects both its recently-pruned pipeline and the ...
Los Angeles—Artificial intelligence (AI)-based drug discovery continues to tout accelerated timelines and novel and effective treatments, yet today’s clinical success rates remain at a low 10%. On ...
Recursion's share price has dropped in recent weeks due to poor clinical trial data, but its most mature assets are not reflective of its current capabilities. Recursion probably needs to advance 5-10 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results